Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOMARIN PHARMACEUTICAL INC Director's Dealing 2012

May 15, 2012

30583_dirs_2012-05-15_e89a0007-b6cd-4e5d-81aa-5b23e16f644e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2012-05-11

Reporting Person: BIENAIME JEAN JACQUES (Director, Chief Executive Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2012-05-11 Common Stock M 10000 $6.46 Acquired 179191 Direct
2012-05-11 Common Stock M 15000 $9.86 Acquired 194191 Direct
2012-05-11 Common Stock S 20000 $38.0097 Disposed 174191 Direct
2012-05-11 Common Stock S 5000 $38.0793 Disposed 169191 Direct
2012-05-11 Common Stock S 500 $38.1312 Disposed 168691 Direct
2012-05-14 Common Stock M 15000 $9.86 Acquired 183691 Direct
2012-05-14 Common Stock S 15000 $38.1262 Disposed 168691 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2012-05-11 Stock Option (right to buy) $9.86 M 15000 Disposed 2015-11-10 Common Stock (15000) Direct
2012-05-11 Stock Option (right to buy) $6.46 M 10000 Disposed 2015-05-10 Common Stock (10000) Direct
2012-05-14 Stock Option (right to buy) $9.86 M 15000 Disposed 2015-11-10 Common Stock (15000) Direct

Footnotes

F1: The price in Column 4 is a weighted average price. The prices actually received ranged from $37.07 to $38.49. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F2: The price in Column 4 is a weighted average price. The prices actually received ranged from $38.04 to $38.13. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3: The price in Column 4 is a weighted average price. The prices actually received ranged from $37.38 to $38.63. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4: Original option grant vested 1/3 each on May 11, 2006, May 11, 2007, and May 11, 2008.

F5: Original option grant vested 1/3 each on May 11, 2006, May 11, 2007, and May 11, 2008.